<DOC>
	<DOCNO>NCT01782690</DOCNO>
	<brief_summary>This observational study evaluate impact rash survival patient metastatic pancreatic cancer treat Tarceva ( erlotinib ) plus gemcitabine . Further , clinical effectiveness , efficacy safety assess . Data collect 12 month .</brief_summary>
	<brief_title>An Observational Study Tarceva ( Erlotinib ) Plus Gemcitabine Patients With Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Adult patient , age &gt; = 18 year Patients metastatic pancreatic cancer investigator decide give combination therapy Tarceva gemcitabine accord Summary Product Characteristics ( SmPC ) Written sign inform consent prior onset documentation Contraindications Tarceva accord Summary Products Characteristics ( SmPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>